Company Overview and News
Investing solely for income, and finding the best dividend stocks, can be tricky. High dividend yields sound attractive on the surface, but almost always come with sharply higher risks. The largest risk is that the very same dividend will be cut. Those cuts usually have a doubled impact. They reduce — or eliminate — the income stream investors were buying in the first place. And as shareholders in companies like General Electric (NYSE:GE), Frontier Communications (NASDAQ:FTR) and Mattel (NASDAQ:MAT) have learned, they often coincide with steep declines in the share price as well.
GIS PG GOOG SBRA AMZN FTRPR GM.WS.A GM.WS.B GM.WS.C GM CVA SBRAP GE F GEC UPS WYNN FDX NYTAB MAT GOOGL TSLA GNE LVS GM.WSB FTR
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549
If you are a Frontier Communications (NASDAQ: FTR) stockholder all I can say is, I’m sorry. To say that the stock has been a poor performer is a massive understatement. Investors who were counting on Frontier’s dividend to save their investment have watched that idea vanish. The company said the right thing when the dividend was eliminated, the savings would be used for debt reduction. While that is one step in the right direction, there are at least two other changes the company needs to make if it wants to stick around.
FTRPR WIN CTL FTR
Tuesday was a relatively flat day for the broad U.S. markets. The Nasdaq hit an all-time high in the session just above 7,700 and the S&P 500 is holding just below the 2,800 mark. Crude oil more or less traded sideways. The S&P 500 sectors were split down the middle. The most positive sectors were utilities and real estate, up 1.1% and 0.6%, respectively. The worst performing sectors were energy and finance, down 0.
APA NDAQ FTRPR FTR
Frontier Communications has been severely depressed with questions about sustainability, with equity sustainability questions revolving around the ability of Frontier to generate sufficient cash flow to redeem future debt maturities.
FTRPR PIY FTR
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
DOCU COST GOOG HPE FTRPR MGA GOOGL GM.WS.A GM.WS.B MG GM.WS.C GM GM.WSB FTR
It has been about a month since the last earnings report for Frontier Communications Corporation (FTR - Free Report) . Shares have lost about 5.8% in that time frame.
IMMR ALIMR FTRPR FTR
In the preceding part, we discussed how Charter Communications’ (CHTR) top line has been improving due to its acquisitions. Charter is witnessing ongoing growth in its core operating profitability, primarily to reflect strong cost management. Charter is expected to have multiple opportunities to create significant merger synergies across the new Charter Communications footprint as it integrates the legacy Time Warner Cable and legacy Bright House Networks acquisitions.
CHTR FTRPR TWC FTR
Frontier Communications (FTR) stock fell 17% last week, which ended on May 25, to close at $7.69. It has returned -62% in the last 12 months and -9.7% in the last month after declining 84% in 2017. FTR is currently trading 26% above its 52-week low of $6.08 and 63% below its 52-week high of $21.
FTRPR WIN FTR
2018-03-04 - Asif
Business Frontier Communications Corporation (Frontier) is a provider of communications services in the United States, with approximately 4.9 million customers, 3.9 million broadband subscribers and 22,700 employees, operating in 29 states. In recent years, Frontier has completed multiple acquisitions. On April 1, 2016, the company acquired the wireline operations of Verizon Communications, Inc. in California, Texas and Florida for a purchase price of $10,540 million in cash and assumed debt. The company conduct business with both consumer and commercial customers. Consumer. The company provide broadband, video, voice and other services and products to its consumer customers. The company deliver these services generally over a combination of fiber and copper-based networks. Commercial (small, medium and large enterprise business (SME) as well as wholesale customers). Com...
2018-06-22 - Asif
Overview Cascadian Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapeutic products for the treatment of cancer. The company's goal is to develop and commercialize novel targeted compounds that have the potential to improve the lives and outcomes of cancer patients. The company's lead clinical-stage product candidate is tucatinib, an oral, HER2-selective small molecule tyrosine kinase inhibitor. The company's pipeline also includes two preclinical-stage product candidates: CASC-578, a Chk1 kinase inhibitor, and CASC-674, an antibody program against an immuno-oncology target known as TIGIT. 2018 Merger Agreement On January 30, 2018, the company entered into an Agreement and Plan of Merger (the Merger Agreement) with Seattle Genetics, Inc., a Delaware corporation (Seattle Genetics), and Valley Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Seattle Genetics (Merger Sub). Pursuant to the Merger ...
2018-06-22 - Asif
Business Overview The Corporation is a Delaware corporation, a bank holding company (BHC) and a financial holding company. When used in this report, “the Corporation” may refer to Bank of America Corporation individually, Bank of America Corporation and its subsidiaries, or certain of Bank of America Corporation’s subsidiaries or affiliates. The company's principal executive offices are located in Charlotte, North Carolina. Through its banking and various nonbank subsidiaries throughout the U.S. and in international markets, the company provide a diversified range of banking and nonbank financial services and products through four business segments: Consumer Banking, Global Wealth & Investment Management (GWIM), Global Banking and Global Markets, with the remaining operations recorded in All Other. The company operate its banking activities primarily under the Bank of America, National Association (Bank of America, N.A. or BANA) charter. At March 31, 2018, the Corporation had a...
2018-06-18 - Asif
Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...
Silicon Investor Message Boards
This table lists all message boards related to FTR / Frontier Communications Corp. on message board site Silicon Investor.
|Futurelink (NASDAQ: FTRL)||FTRL: FutureLink Corporation|
|FTR - Frontier Insurance Group Inc||FutureTrak International, symbol FTRK|
|Firesteel Resources Inc. (ASE)|
as of ET